シンバイオ製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/14 | 724 | 754 | 723 | 740 | +14 | +1.9% | 866,500 |
| 2022/03/11 | 732 | 757 | 723 | 726 | -21 | -2.8% | 977,300 |
| 2022/03/10 | 721 | 752 | 711 | 747 | +46 | +6.6% | 1,617,000 |
| 2022/03/09 | 715 | 721 | 686 | 701 | +4 | +0.6% | 1,277,400 |
| 2022/03/08 | 688 | 724 | 687 | 697 | -6 | -0.9% | 1,477,100 |
| 2022/03/07 | 703 | 713 | 683 | 703 | -30 | -4.1% | 2,084,300 |
| 2022/03/04 | 750 | 754 | 714 | 733 | -28 | -3.7% | 1,633,400 |
| 2022/03/03 | 799 | 803 | 759 | 761 | -15 | -1.9% | 1,631,900 |
| 2022/03/02 | 770 | 795 | 750 | 776 | -12 | -1.5% | 2,398,500 |
| 2022/03/01 | 803 | 824 | 772 | 788 | -9 | -1.1% | 3,794,000 |
| 2022/02/28 | 810 | 856 | 777 | 797 | +2 | +0.3% | 5,285,400 |
| 2022/02/25 | 730 | 795 | 712 | 795 | +100 | +14.4% | 5,029,100 |
| 2022/02/24 | 757 | 769 | 677 | 695 | -94 | -11.9% | 5,941,500 |
| 2022/02/22 | 800 | 827 | 767 | 789 | -42 | -5.1% | 2,695,500 |
| 2022/02/21 | 863 | 876 | 812 | 831 | -86 | -9.4% | 2,940,800 |
| 2022/02/18 | 930 | 951 | 882 | 917 | -45 | -4.7% | 2,897,000 |
| 2022/02/17 | 966 | 1,057 | 940 | 962 | +18 | +1.9% | 9,192,800 |
| 2022/02/16 | 914 | 944 | 899 | 944 | +150 | +18.9% | 3,221,000 |
| 2022/02/15 | 1,100 | 1,127 | 794 | 794 | -300 | -27.4% | 2,488,000 |
| 2022/02/14 | 1,104 | 1,190 | 1,094 | 1,094 | -190 | -14.8% | 3,017,700 |
| 2022/02/10 | 1,213 | 1,290 | 1,207 | 1,284 | +98 | +8.3% | 3,008,900 |
| 2022/02/09 | 1,135 | 1,188 | 1,116 | 1,186 | +51 | +4.5% | 1,296,600 |
| 2022/02/08 | 1,120 | 1,154 | 1,116 | 1,135 | +15 | +1.3% | 822,100 |
| 2022/02/07 | 1,139 | 1,143 | 1,103 | 1,120 | -15 | -1.3% | 794,000 |
| 2022/02/04 | 1,169 | 1,185 | 1,102 | 1,135 | +15 | +1.3% | 1,877,300 |
| 2022/02/03 | 1,112 | 1,123 | 1,065 | 1,120 | +28 | +2.6% | 1,236,600 |
| 2022/02/02 | 1,054 | 1,104 | 1,046 | 1,092 | +50 | +4.8% | 1,110,500 |
| 2022/02/01 | 1,020 | 1,075 | 1,018 | 1,042 | +36 | +3.6% | 1,297,900 |
| 2022/01/31 | 998 | 1,022 | 991 | 1,006 | +10 | +1% | 1,021,900 |
| 2022/01/28 | 1,005 | 1,007 | 984 | 996 | +6 | +0.6% | 642,500 |
| 2022/01/27 | 1,033 | 1,042 | 985 | 990 | -45 | -4.3% | 1,150,300 |
| 2022/01/26 | 998 | 1,043 | 997 | 1,035 | +44 | +4.4% | 917,000 |
| 2022/01/25 | 1,034 | 1,045 | 991 | 991 | -45 | -4.3% | 1,027,200 |
| 2022/01/24 | 1,003 | 1,037 | 996 | 1,036 | +15 | +1.5% | 601,300 |
| 2022/01/21 | 1,023 | 1,042 | 995 | 1,021 | -13 | -1.3% | 852,600 |
| 2022/01/20 | 997 | 1,041 | 995 | 1,034 | +25 | +2.5% | 787,100 |
| 2022/01/19 | 1,026 | 1,037 | 997 | 1,009 | -34 | -3.3% | 1,178,200 |
| 2022/01/18 | 1,043 | 1,089 | 1,032 | 1,043 | +8 | +0.8% | 914,800 |
| 2022/01/17 | 1,075 | 1,081 | 1,035 | 1,035 | -41 | -3.8% | 589,500 |
| 2022/01/14 | 1,081 | 1,091 | 1,066 | 1,076 | -25 | -2.3% | 924,000 |
| 2022/01/13 | 1,107 | 1,126 | 1,091 | 1,101 | -13 | -1.2% | 654,600 |
| 2022/01/12 | 1,095 | 1,125 | 1,091 | 1,114 | +38 | +3.5% | 1,264,800 |
| 2022/01/11 | 1,036 | 1,087 | 1,032 | 1,076 | +35 | +3.4% | 1,184,300 |
| 2022/01/07 | 1,075 | 1,084 | 1,027 | 1,041 | -30 | -2.8% | 1,078,500 |
| 2022/01/06 | 1,075 | 1,104 | 1,068 | 1,071 | -33 | -3% | 1,100,100 |
| 2022/01/05 | 1,155 | 1,155 | 1,094 | 1,104 | -54 | -4.7% | 1,368,400 |
| 2022/01/04 | 1,150 | 1,166 | 1,125 | 1,158 | +13 | +1.1% | 926,400 |
| 2021/12/30 | 1,127 | 1,152 | 1,107 | 1,145 | +4 | +0.4% | 966,900 |
| 2021/12/29 | 1,087 | 1,147 | 1,085 | 1,141 | +52 | +4.8% | 1,365,600 |
| 2021/12/28 | 1,118 | 1,122 | 1,070 | 1,089 | -21 | -1.9% | 1,314,500 |
751～
800
件表示中 / 3293件
類似銘柄と比較する
現在ご覧いただいている「シンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| シンバイオ | 12,600円 | -24.2% | - | 0.00% | - | 1.55倍 |
|
導入で新薬開発・製品化。抗がん剤「トレアキシン」国内販売。抗ウイルス薬ＢＣＶの開発に注力 |
| ケイファーマ | 53,700円 | - | - | 0.00% | - | 2.76倍 |
|
慶応大学発ベンチャー。ｉＰＳ細胞による再生医療と創薬の２本柱。中枢神経系が得意領域 |
| 日ケミファ | 142,300円 | +2.5% | - | 3.51% | 85.57倍 | 0.28倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ソレイジア | 2,700円 | +311.4% | - | 0.00% | - | 5.09倍 |
|
がん柱の創薬ベンチャー。候補品導入後に開発進め権利再導出、製品販売を行うビジネスモデル |
| ＮＰＴ | - | - | - | - | - | - |
|
- |
市場注目の銘柄
チャート関連のコラム
